Home Font Size: 1 2 3 Send to a Friend
Morphotek, Inc., a genomics-based biopharmaceutical company, announced today that it has been awarded a follow-on Opportunity Grant by the...
+ Read the Article
Morphotek Inc. announced today that Wyeth Pharmaceuticals, the pharmaceutical unit of Wyeth (NYSE:WYE), has accepted an evolved cancer cell line from...
Morphotek Inc. announced today that it has been awarded a Phase I Small Business Technology Transfer (STTR) grant from the United States Army. The...
Morphotek Inc. announced today the appointment of Rodney Dausch as Vice President and Chief Financial Officer. Mr. Dausch has over 30 years of...
Morphotek Inc. announced today that it has relocated its headquarters and R&D operations to a newly renovated 41,000 sq. ft. facility located in...
Morphotek Inc. and the Ludwig Institute For Cancer Research (LICR) have entered into a collaborative research and development agreement to develop...
Morphotek Inc. announced today that the Company has received the 2002 Biotech Company of the Year Award at the 8th Annual Ben Franklin Emerging...
Morphotek Inc. and The Wistar Institute today entered into a collaborative research and development agreement to develop improved monoclonal...
Morphotek Inc. announced today the appointment of William Heilman, Ph.D., M.B.A., as Vice President of Business Development. Dr. Heilman has held a...
Morphotek Inc. announced today that David R. King, Esq., has been appointed to its Board of Directors. Mr. King has spent most of his career at...
Results per page 10 25 50